These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 18034577)
1. The cost of Crohn's disease: drugs or surgery? Cohen RD BioDrugs; 2000 Nov; 14(5):331-44. PubMed ID: 18034577 [TBL] [Abstract][Full Text] [Related]
2. Cost of illness of Crohn's disease. Bodger K Pharmacoeconomics; 2002; 20(10):639-52. PubMed ID: 12162753 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease. Loftus EV; Johnson SJ; Yu AP; Wu EQ; Chao J; Mulani PM Eur J Gastroenterol Hepatol; 2009 Nov; 21(11):1302-9. PubMed ID: 19465858 [TBL] [Abstract][Full Text] [Related]
4. Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital. Bernstein CN; Papineau N; Zajaczkowski J; Rawsthorne P; Okrusko G; Blanchard JF Am J Gastroenterol; 2000 Mar; 95(3):677-83. PubMed ID: 10710056 [TBL] [Abstract][Full Text] [Related]
5. Resource use and cost of care with biologicals in Crohn's disease in South Africa: a retrospective analysis from a payer perspective. Miot J; Smith S; Bhimsan N Int J Clin Pharm; 2016 Aug; 38(4):880-7. PubMed ID: 27118462 [TBL] [Abstract][Full Text] [Related]
6. The cost of hospitalization in Crohn's disease. Cohen RD; Larson LR; Roth JM; Becker RV; Mummert LL Am J Gastroenterol; 2000 Feb; 95(2):524-30. PubMed ID: 10685762 [TBL] [Abstract][Full Text] [Related]
7. Economic implications of biological therapies for Crohn's disease: review of infliximab. Bodger K Pharmacoeconomics; 2005; 23(9):875-88. PubMed ID: 16153132 [TBL] [Abstract][Full Text] [Related]
8. Drug treatments for maintaining remission in Crohn's disease. A lifetime cost-utility analysis. Trallori G; Messori A Pharmacoeconomics; 1997 May; 11(5):444-53. PubMed ID: 10168032 [TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling. Ballal RD; Botteman MF; Foley I; Stephens JM; Wilke CT; Joshi AV Curr Med Res Opin; 2008 Mar; 24(3):753-68. PubMed ID: 18234151 [TBL] [Abstract][Full Text] [Related]
10. Economic implications of biological therapy for Crohn's disease. Petryszyn PW; Paradowski L Prz Gastroenterol; 2015; 10(4):197-202. PubMed ID: 26759625 [TBL] [Abstract][Full Text] [Related]
11. Diagnosing Crohn's disease: an economic analysis comparing wireless capsule endoscopy with traditional diagnostic procedures. Goldfarb NI; Pizzi LT; Fuhr JP; Salvador C; Sikirica V; Kornbluth A; Lewis B Dis Manag; 2004; 7(4):292-304. PubMed ID: 15671786 [TBL] [Abstract][Full Text] [Related]
12. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Silverstein MD; Loftus EV; Sandborn WJ; Tremaine WJ; Feagan BG; Nietert PJ; Harmsen WS; Zinsmeister AR Gastroenterology; 1999 Jul; 117(1):49-57. PubMed ID: 10381909 [TBL] [Abstract][Full Text] [Related]
13. Costs of inflammatory bowel disease in Germany. Stark R; König HH; Leidl R Pharmacoeconomics; 2006; 24(8):797-814. PubMed ID: 16898849 [TBL] [Abstract][Full Text] [Related]
14. An evaluation of health care expenditures in Crohn's disease using the United States Medical Expenditure Panel Survey from 2003 to 2013. Bounthavong M; Li M; Watanabe JH Res Social Adm Pharm; 2017; 13(3):530-538. PubMed ID: 27263802 [TBL] [Abstract][Full Text] [Related]
15. Costs of care for Crohn's disease following the introduction of infliximab: a single-centre UK experience. Sprakes MB; Ford AC; Suares NC; Warren L; Greer D; Donnellan CF; Jennings JS; Everett SM; Hamlin PJ Aliment Pharmacol Ther; 2010 Dec; 32(11-12):1357-63. PubMed ID: 21050238 [TBL] [Abstract][Full Text] [Related]
17. Maintenance of remission in Crohn's disease: current and emerging therapeutic options. Brookes MJ; Green JR Drugs; 2004; 64(10):1069-89. PubMed ID: 15139787 [TBL] [Abstract][Full Text] [Related]
18. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement. Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279 [TBL] [Abstract][Full Text] [Related]
19. Cost-utility analysis of biologic treatments for moderate-to-severe Crohn's disease. Tang DH; Armstrong EP; Lee JK Pharmacotherapy; 2012 Jun; 32(6):515-26. PubMed ID: 22528603 [TBL] [Abstract][Full Text] [Related]